Patents Assigned to Vanda Pharmaceuticals, Inc.
  • Method of predicting a predisposition to QT prolongation
    Patent number: 9074255
    Abstract: The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval- prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: July 7, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • Method of predicting a predisposition to QT prolongation
    Patent number: 9074256
    Abstract: The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: July 7, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • Method of predicting a predisposition to QT prolongation
    Patent number: 9074254
    Abstract: The present invention describes an association between genetic polymorphisms in the ceramide kinase-like (CERKL) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: July 7, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Kendra Tomino Mack, Callie Michelle Heaton
  • Treatment of circadian rhythm disorders
    Patent number: 9060995
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: June 23, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype
    Patent number: 9057104
    Abstract: The present invention relates to the treatment of an individual with an antipsychotic based on individual's genotype at one or more single nucleotide polymorphism (SNP) associated with the dopamine receptor D2 (DRD2) and/or ankyrin repeat and kinase domain containing 1 (ANKK1) genes.
    Type: Grant
    Filed: May 15, 2010
    Date of Patent: June 16, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi
  • Method of treatment based on polymorphisms of the KCNQ1 gene
    Patent number: 8999638
    Abstract: The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: April 7, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Curt D. Wolfgang, Mihael H. Polymeropoulos
  • Stable dosage formulations of imidazolylalkyl-pyridines
    Patent number: 8865210
    Abstract: Stable formulations of imidazolylalkyl-pyridines, including controlled-release formulations.
    Type: Grant
    Filed: February 13, 2007
    Date of Patent: October 21, 2014
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian N. Lavedan, Deepak Phadke
  • Treatment of circadian rhythm disorders
    Patent number: 8785492
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: July 22, 2014
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • METHOD AND COMPOSITION FOR TREATING AN ALPHA ADRENOCEPTOR-MEDIATED CONDITION
    Publication number: 20140194459
    Abstract: Methods and compositions for the treatment of alpha-adrenoceptor mediated conditions.
    Type: Application
    Filed: March 5, 2014
    Publication date: July 10, 2014
    Applicant: Vanda Pharmaceuticals, Inc.
    Inventors: Mihael H. Polymeropoulos, Paolo Baroldi, Curt D. Wolfgang
  • Method and composition for treating an alpha adrenoceptor-mediated condition
    Patent number: 8729100
    Abstract: Methods and compositions for the treatment of alpha-adrenoceptor mediated conditions.
    Type: Grant
    Filed: December 13, 2008
    Date of Patent: May 20, 2014
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Mihael H. Polymeropoulos, Paolo Baroldi, Curt D. Wolfgang
  • METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
    Publication number: 20140128433
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Application
    Filed: January 8, 2014
    Publication date: May 8, 2014
    Applicant: Vanda Pharmaceuticals, Inc.
    Inventors: Curt Wolfgang, Mihael Polymeropoulos
  • METHOD AND COMPOSITION FOR TREATING A SEROTONIN RECEPTOR-MEDIATED CONDITION
    Publication number: 20140079685
    Abstract: A method and composition for treating serotonin receptor-mediated conditions.
    Type: Application
    Filed: November 25, 2013
    Publication date: March 20, 2014
    Applicant: Vanda Pharmaceuticals Inc.
    Inventors: Mihael H. Polymeropoulos, Paolo Baroldi, Curt Wolfgang
  • Prediction of QT prolongation based on SNP genotype
    Patent number: 8652776
    Abstract: The present invention relates to the prediction of QT prolongation following administration of a compound capable of increasing an individual's QT interval based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: February 18, 2014
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Kendra Tomino Mack, Callie Michelle Heaton
  • METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
    Publication number: 20140045893
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Application
    Filed: October 23, 2013
    Publication date: February 13, 2014
    Applicant: Vanda Pharmaceuticals, Inc.
    Inventors: Curt Wolfgang, Mihael Polymeropoulos
  • METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
    Publication number: 20140039008
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Application
    Filed: October 2, 2013
    Publication date: February 6, 2014
    Applicant: VANDA PHARMACEUTICALS, INC.
    Inventors: Curt Wolfgang, Mihael Polymeropoulos, Christian Lavedan, Simona Volpi
  • Method and composition for treating a serotonin receptor-mediated condition
    Patent number: 8618134
    Abstract: A method and composition for treating serotonin receptor-mediated conditions.
    Type: Grant
    Filed: December 13, 2008
    Date of Patent: December 31, 2013
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Mihael H. Polymeropoulos, Paolo Baroldi, Curt Wolfgang
  • Methods for the administration of iloperidone
    Patent number: 8586610
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: November 19, 2013
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Curt D. Wolfgang, Mihael H. Polymeropoulos
  • Ruthenium (II) catalysts for use in stereoselective cyclopropanations
    Patent number: 8558017
    Abstract: Chiral ruthenium catalysts comprising salen and alkenyl ligands are provided for stereoselective cyclopropanation, and methods of cyclopropanation are provided. The chiral ruthenium catalyst is prepared in situ by combining an alkenyl ligand, a deprotonated chiral salen ligand, and a ruthenium (II) metal. A preferred catalyst is prepared in situ by combining 2,3-dihydro-4-venylbenzofuran,deprotonated 1,2-cyclohexanediamino-N,N?-bis(3,5-di-t-butyl-salicylidene) and RuCl2(p-cymene)]2.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: October 15, 2013
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: David E. Pereira, Wade Aumiller, Raymond Dagger
  • TREATMENT OF CIRCADIAN RHYTHM DISORDERS
    Publication number: 20130197076
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Application
    Filed: January 25, 2013
    Publication date: August 1, 2013
    Applicant: Vanda Pharmaceuticals, Inc.
    Inventor: Vanda Pharmaceuticals, Inc.
  • USE OF A MELATONIN AGONIST FOR THE TREATMENT OF SLEEP DISORDERS INCLUDING PRIMARY INSOMNIA
    Publication number: 20120136050
    Abstract: Embodiments of the invention include the treatment of a sleep disorder comprising the administration of N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cycloproply]methyl]propanamide or a salt, stereoisomer, solvate, or hydrate thereof, in amorphous or crystalline form.
    Type: Application
    Filed: July 16, 2010
    Publication date: May 31, 2012
    Applicant: VANDA PHARMACEUTICALS INC.
    Inventors: Mihael H. Polymeropoulos, Gunther Birznieks, Deepak Phadke